From: Neuromuscular blockade management in the critically Ill patient
Agent | ED95a (mg/kg) | Onset time | Infusion dose (μg/kg/min) | Clinical duration | Notes |
---|---|---|---|---|---|
Succinylcholine | 0.5–0.6 | 30–60 s | NR | Dose dependent; 3 × ED95 lasts 12–15 min | Transiently increases serum K levels by 0.5 mEq, can be used for RSII, metabolized by butyrylcholinesterasec |
Rocuronium | 0.3b | 1.5–3 min | 5–12 | 20–70 min | Can be used for RSII, eliminated by the liver (90%) and kidneys (10%) |
Vecuronium | 0.05 | 3–4 min | 1–2 | 25–50 min | Active metabolites, associated with ICUAW |
Mivacurium | 0.08 | 3–4 min | 5–8 | 15–20 | Metabolized by butyrylcholinesterasec, associated with histamine release |
Cisatracurium | 0.05 | 4–7 min | 1–3 | 35–50 min | Hofmann elimination |
Atracurium | 0.25 | 3–5 min | 10–20 | 30–45 min | Metabolized by plasma esterase and Hofmann elimination, associated with histamine release |
Pancuronium | 0.07 | 2–4 min | 20–40 (not recommended) | 60–120 min | Active metabolites, associated with ICUAW, vagolytic effect causes tachycardia |